Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, the RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday.
The institute completed early-stage human trials, known as Phase II, earlier this month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.